Onchilles Pharma
Developing drug candidates that have the potential to be broadly effective against a wide range of cancers.
Developing drug candidates that have the potential to be broadly effective against a wide range of cancers.
Onchilles Pharma, founded in 2017 and headquartered in the United States, is a private biotech company focused on developing drug candidates with the potential to effectively combat a broad spectrum of cancers. The company's slogan, "Developing drug candidates that have the potential to be broadly effective against a wide range of cancers," reflects its core mission. Onchilles Pharma's groundbreaking research on a novel neutrophil pathway has paved the way for the development of a pipeline of first-in-class drug candidates with promising potential. The company's last investment round, a $7.00M Series A investment, took place on 10 July 2020 and was led by LYZZ CAPITAL and UChicago Startup Investment Program. Onchilles Pharma's work in the Biopharma, Biotechnology, and Pharmaceutical industries positions it as a key player in the fight against cancer. With its focus on innovative drug development, the company is poised to make significant strides in the field of oncology.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $7.00M | 2 |
|
10 Jul 2020 |
| Grant | $150.00K | 1 | Polsky Center at the University of Chicago | 06 Dec 2017 |
No recent news or press coverage available for Onchilles Pharma.
We care about your data, and we'd love to use cookies make your experience better.
